RNA-targeted oligonucleotide drugs represent the third bona fide drug discovery platform in the pharmaceutical industry. No less than 14 oligonucleotide drugs have been approved by regulatory agencies and over 100 are in clinical development. However, finding a way to effectively deliver these types of drugs provides a major challenge.
Join Vice President of Medicinal Chemistry Punit Seth of Ionis Pharmaceuticals as he discusses examples of different strategies for delivery of oligonucleotide drugs. Learn about the recent advances in receptor-mediated delivery which have greatly expanded the repertoire of cell-types and tissues that are now accessible for antisense drug-discovery. This
ACS Webinar is moderated Associate Director of Clinical Pharmacology and Pharmacokinetics Charvi Nanavati of Ionis Pharmaceuticals and co-produced with the ACS Division of Medicinal Chemistry, American Association of Pharmaceutical Scientists, and ACS Publications.
What You Will Learn
- What are the general principles for delivery of RNA-targeted oligonucleotide drugs
- How local delivery occurs to tissues such as the lung and the CNS
- How receptor-mediated delivery to hepatocytes, pancreatic beta cells, skeletal muscle and heart tissues occur